98%
921
2 minutes
20
We investigated the relationship between asthma mortality and long-acting beta(2)-agonists (LABA), including interactions with age, inhaled corticosteroids (ICS) and social deprivation. We used a new, expanded dataset of recorded medication extracted blind from the anonymised primary care records of an earlier British case-control study. The cases were 532 asthma deaths aged < 65 occurring between 1994 and 1998 and the controls were 532 asthma admissions, matched for age, hospital, and index date (date of death/asthma admission). The exposure periods prior to the index date were current (≤ 2 months) or recent ( > 2-6 months). We found no evidence of an overall association with current (OR = 0.89 [95% confidence interval 0.61-1.30]) or recent (1.08 [0.76-1.53]) mention of LABA, but there was some evidence of a positive interaction with age. Among controls with mention of LABA, a concurrent mention of ICS (within 1 month) was common (85% and 93% for the two respective periods) which limited our power to investigate any interaction between LABA and ICS. There was no coherent evidence of effect modification by social deprivation. In a population based case-control study where prescription of LABA without concomitant ICS was uncommon there was no evidence of an overall association between LABA and asthma death.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rmed.2010.10.008 | DOI Listing |
JMIR Cancer
September 2025
Department of Health Outcomes and Biomedical Informatics, University of Florida, 1889 Museum Road, Suite 7000, Gainesville, FL, 32611, United States, 1 352 294-5969.
Background: Disparities in cancer burden between transgender and cisgender individuals remain an underexplored area of research.
Objective: This study aimed to examine the cumulative incidence and associated risk factors for cancer and precancerous conditions among transgender individuals compared with matched cisgender individuals.
Methods: We conducted a retrospective cohort study using patient-level electronic health record (EHR) data from the University of Florida Health Integrated Data Repository between 2012 and 2023.
Ann Intern Med
September 2025
Johns Hopkins University School of Medicine, Baltimore, Maryland (M.S., J.J., K.A.G., M.S., A.T.F.).
Background: With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States.
Objective: To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months.
Neurology
October 2025
Norcliffe Foundation Center for Integrative Brain Research, Seattle Children's Research Institute, WA.
Background And Objectives: Neuroimaging findings in immune effector cell-associated neurotoxicity syndrome (ICANS) have not been systematically described. We created the chimeric antigen receptor (CAR) T-cell Neurotoxicity Imaging Virtual Archive Library (CARNIVAL), a centralized imaging database for children and young adults receiving CAR T-cell therapy. Objectives of this study were to (1) characterize neuroimaging findings associated with ICANS and (2) determine whether specific ICANS-related neuroimaging findings are associated with individual neurologic symptoms.
View Article and Find Full Text PDFNeurology
October 2025
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
Objectives: Status epilepticus (SE) is a life-threatening neurologic emergency. Although health disparities in epilepsy are well-documented, disparities in SE mortality are not fully understood. This study analyzes mortality trends and demographics in the United States from 1999 through 2020.
View Article and Find Full Text PDFNeurology
October 2025
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain.
Background And Objectives: α-Synuclein seed amplification assays (αSAAs) can improve the diagnosis of synucleinopathies and detect α-synuclein (αSyn) copathology in vivo in clinical practice. We aimed to evaluate the diagnostic performance of αSAA for detecting αSyn in CSF for diagnosing dementia with Lewy bodies (DLB) in a clinical cohort of cognitively impaired individuals. We explored how the coexistence of Alzheimer disease (AD) and αSyn pathology influences biomarker levels and clinical profiles.
View Article and Find Full Text PDF